Bottom line
FBIOX vs BIB: the short answer
FBIOX (Biotechnology Portfolio) and BIB (ProShares Ultra Nasdaq Biotechnology) are quite different portfolios: only about 30% of their top holdings (by weight) are shared.
FBIOX is cheaper at 0.62% vs 0.95% — a difference of $33 a year per $10,000 invested.
Over five years, FBIOX returned +3.5% a year vs −1.0% for BIB (reporting dates differ).
Updated Nov 19, 2026
FBIOX vs BIB side by side
| FBIOX | BIB | |
|---|---|---|
| Type | Mutual fund | ETF |
| Fund family | Fidelity | ProShares |
| Category | Technology Sector | Technology Sector |
| Expense ratio | 0.62% | 0.95% |
| Annual cost per $10k | $62 | $95 |
| 10-yr cost on $10k (prospectus) | $774 | $1,401 |
| Max front load | — | None |
| 12b-1 fee | 0% | — |
| 1-yr return | +36.4% | +59.3% |
| 5-yr return (annualized) | +3.5% | −1.0% |
| 10-yr return (annualized) | +6.9% | +1.4% |
| Best quarter | +33.6% | +56.2% |
| Worst quarter | −28.4% | −42.7% |
| Net assets (fund) | $5.3B | $73.7M |
| Number of holdings | 215 | 267 |
| Portfolio turnover | 45% | 29% |
| Returns as of | Apr 30, 2026 | Dec 31, 2025 |
Source: SEC Form N-PORT and fund prospectuses
Year-by-year returns
| Year | FBIOX | BIB | Difference |
|---|---|---|---|
| 2025 | +36.4% | +59.3% | −23.0% |
| 2024 | +7.3% | −10.0% | +17.3% |
| 2023 | +10.1% | −1.3% | +11.4% |
| 2022 | −15.9% | −28.6% | +12.8% |
| 2021 | −12.4% | −5.9% | −6.5% |
| 2020 | +38.3% | +39.7% | −1.4% |
| 2019 | +36.0% | +45.5% | −9.6% |
| 2018 | −10.7% | −24.4% | +13.6% |
| 2017 | +27.9% | +40.8% | −12.9% |
| 2016 | −23.7% | −44.2% | +20.5% |
Source: Fund prospectus bar charts
Holdings overlap
9 of FBIOX's top 25 holdings also appear in BIB's top 25.
| Holding | FBIOX | BIB |
|---|---|---|
| Amgen Inc | 6.53% | 4.48% |
| Gilead Sciences Inc | 4.82% | 4.66% |
| Alnylam Pharmaceuticals Inc | 2.93% | 2.01% |
| Insmed Inc | 2.25% | 1.16% |
| Argenx Se | 2.25% | 1.19% |
| Revolution Medicines Inc | 2.02% | 1.57% |
| Moderna Inc | 1.28% | 0.94% |
| Biogen Inc | 1.26% | 1.44% |
| Roivant Sciences Ltd | 1.13% | 1.08% |
Source: SEC Form N-PORT
FBIOX top 10
- Krystal Biotech Inc — 10.58%
- Abbvie Inc — 9.22%
- Amgen Inc — 6.53%
- Gilead Sciences Inc — 4.82%
- Fidelity Revere Street Trust — 3.35%
- Alnylam Pharmaceuticals Inc — 2.93%
- Praxis Precision Medicines Inc. — 2.47%
- Insmed Inc — 2.25%
- Argenx Se — 2.25%
- Ascendis Pharma A/s — 2.04%
BIB top 10
- N/a — 7.35%
- ProShares GENIUS Money Market ETF — 6.80%
- Gilead Sciences, Inc. — 4.66%
- Vertex Pharmaceuticals, Inc. — 4.65%
- Amgen, Inc. — 4.48%
- N/a — 3.94%
- N/a — 3.26%
- Regeneron Pharmaceuticals, Inc. — 3.21%
- N/a — 2.62%
- Alnylam Pharmaceuticals, Inc. — 2.01%
FAQ
What is the difference between FBIOX and BIB?
Which is cheaper, FBIOX or BIB?
Should I own both FBIOX and BIB?
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.